Diabetic Medicine最新文献

{"title":"Clinical effects of SGLT2 inhibitors in seven persons with HNF1A-MODY (MODY3)","authors":"Henrik Maagensen, Sofie Hædersdal, Jesper Krogh, Torben Hansen, Filip Krag Knop, Anne Cathrine Baun Thuesen, Tina Vilsbøll","doi":"10.1111/dme.15387","DOIUrl":"10.1111/dme.15387","url":null,"abstract":"<p>Maturity-onset diabetes of the young (MODY) is a heterogeneous subset of monogenic diabetes characterized by early onset of diabetes, typically between the second and fifth decade of life. Pathogenic variants in <i>HNF1A</i> cause one of the most prevalent MODY types named HNF1A-MODY (or MODY3).<span><sup>1</sup></span> Sulfonylureas (SU) are typically used as the primary treatment,<span><sup>2</sup></span> while incretin-based treatments have also been shown to lower glucose levels.<span><sup>3, 4</sup></span> In type 2 diabetes, sodium-glucose cotransporter 2 (SGLT2) inhibitors are effective glucose-lowering agents. However, the utility and safety of SGLT2 inhibitors in HNF1A-MODY are scarcely described.<span><sup>5-7</sup></span> Here, we describe seven individuals with HNF1A-MODY treated with SGLT2 inhibitors as add-ons to SU, insulin and incretin-based therapies.</p><p>At initiation of SGLT2 inhibitor, all persons (<i>n</i> = 7) were treated with SU (glimepiride) and incretin-based therapy, four persons were treated with insulin and one with metformin (Table 1). Estimated glomerular filtration rate (eGFR) was >90 mL/min/1.73 m<sup>2</sup> for all but one individual with eGFR in the range of 45–60 mL/min/1.73 m<sup>2</sup>. The persons carried the following <i>HNF1A</i> variants: c.956-2A>G (<i>n</i> = 2), p.Glu332Ter, p.Leu12Phe, p.Pro379Ala, p.Pro379fs, p.Tyr218Cys (RefSeq NM_000545.5). All individuals started the SGLT2 inhibitor empagliflozin at a dose of 10 mg once daily. After 4 months, HbA1c had decreased in six individuals, BMI decreased in all participants, and three of four insulin-treated persons had discontinued insulin therapy (Table 1). After 1 year, the daily insulin dose was reduced from 15 units/day (four injections daily) to 2 units/day (one injection daily) in the remaining insulin-treated individual. After 1 year, HbA1c was markedly lower in three individuals (range −2.6%; −0.8% [−28; −9 mmol/mol]), including one person discontinuing insulin therapy), remained at baseline level (within 0.3% [3 mmol/mol]) in three participants (including two persons discontinuing insulin therapy) and was increased (1.1% [12 mmol/mol]) in the person with impaired kidney function in whom insulin dose was lowered.</p><p>During the follow-up period (14 person-years), 11 adverse events were identified of which none were considered serious (death, life-threatening or leading to hospitalization) or led to permanent discontinuation of the SGLT2 inhibitor. Five adverse events were considered related to empagliflozin: balanitis (<i>n</i> = 1, single occasion), cystitis (three instances in two males, symptoms confirmed by either dipstick or urine culture) and mild polyuria (<i>n</i> = 1). Other adverse events considered not to be related to empagliflozin included non-specific dizziness (<i>n</i> = 2, single occasions, hypoglycaemia and volume-depletion were excluded as the cause), gastroenteritis (<i>n</i> = 2, no signs of volume depletion, no","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15387","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141320693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Closing the policy gap in diabetes care for individuals with advanced CKD.","authors":"Hellena Hailu Habte-Asres, Miranda Rosenthal, Dorothea Nitsch, David C Wheeler","doi":"10.1111/dme.15381","DOIUrl":"https://doi.org/10.1111/dme.15381","url":null,"abstract":"<p><strong>Aim: </strong>The co-existence of diabetes and CKD poses significant challenges to healthcare systems, current frameworks often inadequately address the complex needs of individuals with both conditions. Recognising these gaps, we introduced a new diabetes care model for people with advanced CKD in renal satellite units.This paper aims to evaluate this new diabetes model care.</p><p><strong>Method: </strong>We conducted a prospective audit of a new integrated diabetes kidney care model. Data were presented as mean ± SD or counts/percentages, and pre- and post-intervention differences were assessed using paired samples t-tests.</p><p><strong>Results: </strong>A total of 291 individuals with diabetes and advanced CKD stages 4 or 5, or undergoing haemodialysis, were included. The mean age was 68.5 (±13.0) years, 58.4% were males. Nearly half of the cohort had four or more long-term conditions, while two-thirds experienced mild/severe frailty. Only 6% were receiving ongoing diabetes care from secondary care diabetes specialist services. For patients with CKD not receiving dialysis, comparing pre- and post-intervention, there were improvements in HbA1c (-13.0 mmol/mol, p < 0.001), SBP (-13.7 mm Hg, p < 0.0001), and weight (-2.9 kg, p < 0.0001). Furthermore, there was an increase in guideline-directed therapies, with notable usage of SGLT2i (62.9%) and GLP1-RA (28.4%), while access to diabetes technology increased to 89%.</p><p><strong>Conclusion: </strong>This new model of care resulted in improved metabolic outcomes, increased utilisation of guideline-directed therapies, and enhanced access to diabetes technologies. However, the model also revealed significant unmet clinical needs in areas such as access to diabetes care, diabetes eye screening and foot surveillance.</p>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of sodium–glucose co-transporter-2 inhibitors in kidney transplant recipients with diabetes mellitus","authors":"SophieAnne Buckley,&nbsp;Yuvanaa Subramaniam,&nbsp;Ritwika Mallik,&nbsp;Dorcas Mukuba,&nbsp;Mahalia Casabar,&nbsp;Omer Ali,&nbsp;Connor Byrne,&nbsp;Tahseen A. Chowdhury","doi":"10.1111/dme.15383","DOIUrl":"10.1111/dme.15383","url":null,"abstract":"","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of preoperative haemoglobin A1c levels on postoperative outcomes in adults undergoing major noncardiac surgery: A systematic review","authors":"Abby Yu,&nbsp;Quynh Truong,&nbsp;Karen Whitfield,&nbsp;Andrew Hale,&nbsp;Meng-Wong Taing,&nbsp;Natalie Barker,&nbsp;Michael D’Emden","doi":"10.1111/dme.15380","DOIUrl":"10.1111/dme.15380","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Diabetes is known to increase morbidity and mortality after major surgery. However, literature is conflicting on whether elevated preoperative haemoglobin A_1c (HbA_1c) levels are associated with worse outcomes following major noncardiac surgery. We aimed to investigate the effect of incremental preoperative HbA_1c levels on postoperative outcomes in adults who had undergone major noncardiac surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We systematically searched PubMed, EMBASE and the Cochrane Library databases for eligible studies published between January 2012 and July 2023. Randomised controlled trials and observational studies (cohort and case–control studies) which measured HbA_1c within 6 months before surgery and compared outcomes between at least three incremental subgroups or analysed HbA_1c as a continuous variable were included. The systematic review protocol was registered with PROSPERO (CRD42023391946).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty observational studies investigating outcomes across multiple surgical types were included. Higher preoperative HbA_1c levels were associated with increased odds of overall postoperative complications, postoperative acute kidney injury, anastomotic leak, surgical site infections and increased length of stay. Each 1% increase in preoperative HbA_1c was associated with increased odds of these complications. No association with reoperations and 30-day mortality was identified. The literature was highly variable with respect to composite major complications, perioperative cardiovascular events, hospital readmissions, postoperative pneumonia and systemic thromboembolism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Current evidence suggested that higher preoperative HbA_1c levels were associated with increased odds of postoperative complications and extended length of stay in adults undergoing major noncardiac surgery. Further high-quality studies would be needed to quantify the risks posed and determine whether early intervention improves outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15380","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial","authors":"Ruth Frampton,&nbsp;Jennifer R. Snaith,&nbsp;Samantha Hocking,&nbsp;Jane Holmes-Walker,&nbsp;Nicholas Olsen,&nbsp;Jerry R. Greenfield","doi":"10.1111/dme.15377","DOIUrl":"10.1111/dme.15377","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Premature cardiovascular disease is the leading cause of death in people living with type 1 diabetes. Therapies are urgently needed to address cardiovascular risk in this group. Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, has been shown to reduce cardiovascular events and improve weight and glycaemia in type 2 diabetes. Semaglutide may offer cardioprotective and metabolic benefits in type 1 diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We will study 60 adults aged 25–70 years with type 1 diabetes of duration at least 2 years, body mass index ≥25 kg/m², HbA_1c ≥7% and at least one cardiovascular risk factor (microalbuminuria, hypertension or anti-hypertensive treatment, hyperlipidemia or lipid lowering therapy, current smoking). Participants will receive semaglutide up to 1.0 mg weekly or matched placebo for 26 weeks. The primary outcome is carotid femoral pulse wave velocity, a measure of arterial stiffness, as a surrogate marker of cardiovascular risk. Potential mechanisms for metabolic changes will be explored including change in insulin sensitivity determined by hyperinsulinaemic-euglycaemic clamp; and incretin and pancreatic hormone action measured during mixed meal tolerance test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The REducing cardiometabolic risk with SEmaglutide in Type 1 diabetes study will investigate whether semaglutide, a long acting glucagon-like peptide receptor agonist, can improve markers of cardiometabolic health in T1D. Underlying mechanisms predicting response, including insulin resistance and incretin hormone status, will also be explored.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15377","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The experiences of individuals who have had gestational diabetes: A qualitative exploration","authors":"Anna Roesler,&nbsp;Kaley Butten,&nbsp;Pennie Taylor,&nbsp;Melinda Morrison,&nbsp;Marlien Varnfield,&nbsp;Elizabeth Holmes-Truscott","doi":"10.1111/dme.15374","DOIUrl":"10.1111/dme.15374","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To qualitatively explore the experiences of individuals with Gestational Diabetes Mellitus (GDM) in Australia, and to recognise opportunities for leveraging digital health to enhance the support of GDM management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A cross sectional online survey assessed the experiences of individuals with GDM, the healthcare system and their digital health usage. Respondents (recruited via a national diabetes registry or social media) were adults receiving GDM care within Australia in the last 5 years, who responded to any of three open-ended questions (<i>n</i> = 815) exploring positive, negative and other GDM experiences. Thematic analysis was utilised, and themes were mapped to the socio-ecological systems framework.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At a system level, themes related to (1) <i>accessibility of care</i> including the value of digital health and the inflexible or inconsistent perception of the (2) <i>implementation of guidelines</i>. At an interpersonal level, themes covered the need for adequate (3) <i>health information provision,</i> and (4) <i>supportive care</i>, as well as highlighting (5) <i>experiences of stigma</i> including a desire for greater awareness of GDM. Individual-level themes included: (6) differential <i>barriers to accessing care;</i> (7) negative <i>emotional burden</i>; (8) <i>internalisation of stigma</i>; (9) <i>dietary freedom and social impact</i> and (10) <i>opportunity for change</i> derived from having GDM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Findings suggest a demand for more supportive, person-centred GDM care, improved information provision and individualised implementation of clinical guidelines. Such mechanisms may support reduced barriers to accessing care or negative psychosocial impacts of GDM. Though not central to the identified experiences, digital health tools may help address the need for optimised GDM care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15374","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ambulance clinician use of capillary blood ketone meters to improve emergency hyperglycaemia care: A stepped-wedged controlled, mixed-methods feasibility study","authors":"Larissa Stella Prothero,&nbsp;Thomas Strudwick,&nbsp;Theresa Foster,&nbsp;Andrea Kathleen Lake,&nbsp;Adrian Boyle,&nbsp;Allan Clark,&nbsp;Julia Williams,&nbsp;Gerry Rayman,&nbsp;Ketan Dhatariya","doi":"10.1111/dme.15372","DOIUrl":"10.1111/dme.15372","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To determine whether it was feasible, safe and acceptable for ambulance clinicians to use capillary blood ketone meters for ‘high-risk’ diabetic ketoacidosis (DKA) recognition and fluid initiation, to inform the need for a full-powered, multi-centre trial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Adopting a stepped-wedge controlled design, participants with hyperglycaemia (capillary blood glucose &gt;11.0 mmol/L) or diabetes and unwell were recruited. ‘High-risk’ DKA intervention participants (capillary blood ketones ≥3.0 mmol/L) received paramedic-led fluid therapy. Participant demographic and clinical data were collated from ambulance and hospital care records. Twenty ambulance and Emergency Department clinicians were interviewed to understand their hyperglycaemia and DKA care experiences.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In this study, 388 participants were recruited (Control: <i>n</i> = 203; Intervention: <i>n</i> = 185). Most presented with hyperglycaemia, and incidence of type 1 and type 2 diabetes was 18.5% and 74.3%, respectively. Ketone meter use facilitated ‘high-risk’ DKA identification (control: 2.5%, <i>n</i> = 5; intervention: 6.5%, <i>n</i> = 12) and was associated with improved hospital pre-alerting. Ambulance clinicians appeared to have a high index of suspicion for hospital-diagnosed DKA participants. One third (33.3%; <i>n</i> = 3) of Control and almost half (45.5%; <i>n</i> = 5) of Intervention DKA participants received pre-hospital fluid therapy.</p>\u0000 \u0000 <p>Key interview themes included clinical assessment, ambulance DKA fluid therapy, clinical handovers; decision support tool; hospital DKA management; barriers to hospital DKA care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Ambulance capillary blood ketone meter use was deemed feasible, safe and acceptable. Opportunities for improved clinical decision making, support and safety-netting, as well as in-hospital DKA care, were recognised. As participant recruitment was below progression threshold, it is recommended that future-related research considers alternative trial designs. Clinicaltrials.gov: NCT04940897.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15372","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes and risk of hospitalisation due to infection in northeastern Thailand: Retrospective cohort study using population-based healthcare service data","authors":"Pimnara Peerawaranun,&nbsp;Wirichada Pan-ngum,&nbsp;Viriya Hantrakun,&nbsp;Sarah H. Wild,&nbsp;Susanna Dunachie,&nbsp;Parinya Chamnan","doi":"10.1111/dme.15378","DOIUrl":"10.1111/dme.15378","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Population-based studies describing the association between diabetes and increased risk of infection have largely been based in high-income countries. There is limited information describing the burden of infectious disease attributable to diabetes in low and middle-income countries. This study aimed to describe the burden and risk of infectious disease hospitalisation in people with diabetes compared to those without diabetes in northeastern Thailand.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In a retrospective cohort study using electronic health record data for 2012–2018 for 3.8 million people aged ≥20 years in northeastern Thailand, hospitalisation rates for any infectious diseases (ICD-10 codes A00-B99) were estimated and negative binomial regression used to estimate rate ratios (RR) for the association between diabetes and infectious disease hospitalisation adjusted for age, sex and area of residence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In this study, 164,177 people had a diagnosis of diabetes mellitus at any point over the study period. Infectious disease hospitalisation rates per 1000 person-years (95%CI) were 71.8 (70.9, 72.8), 27.7 (27.1, 28.3) and 7.5 (7.5, 7.5) for people with prevalent diabetes, incident diabetes and those without diabetes respectively. Diabetes was associated with a 4.6-fold higher risk of infectious disease hospitalisation (RR (95% CI) 4.59 (4.52, 4.66)). RRs for infectious disease hospitalisation were 3.38 (3.29, 3.47) for people with diabetes managed by lifestyle alone and 5.29 (5.20, 5.39) for people receiving prescriptions for diabetes drugs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this Thai population, diabetes was associated with substantially increased risk of hospitalisation due to infectious diseases and people with diabetes who were on pharmacological treatment had a higher risk than those receiving lifestyle modification advice alone.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘Producing a preference-based quality of LIFE measure to quantify the impact of HYPOGLYCAEMIA on people living with diabetes: A mixed-methods research protocol’ Carlton, J, Powell, P, Rowen, D, Broadley, M, Pouwer, F, Speight, J, Heller, S, Gall, MA, Rosilio, M, Child, CJ, Comins, J, McCrimmon, RJ, Galan, B, Brazier, J; Hypo-RESOLVE CONSORTIUM. Producing a preference-based quality of LIFE measure to quantify the impact of HYPOGLYCAEMIA on people living with diabetes: a mixed-methods research protocol. Diabet Med 2023 Mar; 40(3):e15007. doi: 10.1111/dme.15007.","authors":"","doi":"10.1111/dme.15351","DOIUrl":"10.1111/dme.15351","url":null,"abstract":"","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors affecting continuous participation in follow-up evaluations during a lifestyle intervention programme for type 2 diabetes prevention: The Feel4Diabetes-study","authors":"Elias Kourpas,&nbsp;Konstantinos Makrilakis,&nbsp;George Dafoulas,&nbsp;Violeta Iotova,&nbsp;Kaloyan Tsochev,&nbsp;Roumyana Dimova,&nbsp;Greet Cardon,&nbsp;Esther M. González-Gil,&nbsp;Luis Moreno,&nbsp;Jemina Kivelä,&nbsp;Jaana Lindström,&nbsp;Imre Rurik,&nbsp;Emese Antal,&nbsp;Patrick Timpel,&nbsp;Peter Schwartz,&nbsp;Christina Mavrogianni,&nbsp;Yannis Manios,&nbsp;Stavros Liatis,&nbsp;the Feel4Diabetes-study Group","doi":"10.1111/dme.15368","DOIUrl":"10.1111/dme.15368","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim<b>s</b></h3>\u0000 \u0000 <p>Community- and school-based lifestyle interventions are an efficient method of preventing type 2 diabetes in vulnerable populations. Many participants, however, fail to complete the necessary follow-ups. We investigated factors affecting the continuous participation in follow-up evaluations during the Feel4Diabetes-study, a multilevel intervention programme implemented across Europe.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Socioeconomic, sociodemographic and clinical factors were assessed for 2702 participants within six participating countries: Bulgaria and Hungary (low-to-middle-income countries, LMIC), Belgium and Finland (high-income countries, HIC) and Greece and Spain (high-income countries under austerity measures, HICAM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Statistically significant differences were detected with respect to sex, control group, education level, employment status, BMI and blood pressure measurements (systolic and diastolic blood pressure). Post hoc analysis revealed significant differences within socioeconomic regions. Higher levels of education were associated with significantly lower attrition in HIC (<i>p</i> &lt; 0.05) and HICAM (<i>p</i> &lt; 0.001), higher employment status was associated with lower attrition in HICAM (<i>p</i> &lt; 0.001) and being female was associated with lower attrition in LMIC (<i>p</i> &lt; 0.001). Surprisingly, the intervention group exhibited higher-than-expected attrition in HIC (<i>p</i> &lt; 0.001) and HICAM (<i>p</i> = 0.003), and lower attrition in LMIC (<i>p</i> = 0.007). When tested together in the same multivariable predictive model, all sociodemographic and socioeconomic variables along with higher BMI retained their statistical significance, while systolic and diastolic blood pressure failed to remain significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Key socioeconomic and sociodemographic factors along with BMI play a significant role in determining continuous participation in follow-up evaluations during school- and community-based intervention programmes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11251,"journal":{"name":"Diabetic Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dme.15368","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141261060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}